Novant Health, UNC Health, UNC School of Medicine announce agreement to partner across North Carolina

Novant Health, UNC Health and UNC School of Medicine have reached an agreement to expand medical education, research and clinical services to Novant Health facilities and other locations across North Carolina.

This partnership will expand the recently approved relationship between these organizations in New Hanover County to include Mecklenburg, Forsyth and other counties, with an additional focus to find innovative solutions to enhance care in rural areas.

The partnership will begin with locating a UNC School of Medicine branch campus at Novant Health Presbyterian Medical Center in Charlotte and will enhance and serve as an important training site for learners. It also gives more students access to learn at the best medical school for primary care in the country, according to U.S. News & World Report, and will expand the pipeline for high-quality physicians available to serve North Carolinians. In addition, the expansion of UNC School of Medicine’s Kenan Primary Care Medical Scholars Program will train more students to work in rural and under-resourced communities with enhanced training for care in those communities across North Carolina.

Additionally, clinical trials and studies from UNC School of Medicine’s world-renowned researchers will provide new treatment options for patients in Novant Health facilities.

Collaboration on population health has the potential to make a tremendous impact on the health of North Carolina. Together, through advanced analytics and proven population health strategies, more data will allow these partners to address community health challenges, such as COVID-19, opioid addiction, social determinants of health and health equity, to name a few.

“I am pleased that Forsyth and Mecklenburg counties, and the surrounding communities, will benefit from a collaboration between Novant Health and UNC Health and School of Medicine,” said Carl S. Armato, Novant Health president and CEO. “Our organizations are culturally aligned and committed to delivering safe, high-quality and affordable care while improving health equity in the communities we serve. This alignment allows us to expand access to medical education and clinical research across the state.”

“I am excited for the opportunities ahead for Novant Health, UNC Health and UNC School of Medicine to build a healthier North Carolina and to train more physicians for North Carolina,” said Dr. Wesley Burks, CEO of UNC Health and dean of UNC School of Medicine. “Our partnership will impact health in North Carolina for decades to come.”

More details will be announced as the partnership is finalized.

Source Article

Read more

TFF Pharmaceuticals, Inc. and Augmenta Bioworks, Inc. Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies

Companies to collaborate in first-of-its-kind uses of Thin Film Freezing technology applied to monoclonal antibodies

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company, and Augmenta Bioworks, Inc., a biotechnology company enabling breakthroughs in medicine through immune profiling, today jointly announce that both companies have entered into a worldwide Joint Development and Collaboration Agreement to develop novel commercial products incorporating Augmenta’s human-derived monoclonal antibodies (mAbs) for potential COVID-19 therapeutics.

Under the terms of the Agreement, both companies will collaborate in a Joint Development Project to develop one or more commercial therapeutics based on, derived from, and/or incorporating Augmenta’s human monoclonal antibodies to potentially treat patients with COVID-19. These products will be developed utilizing TFF Pharmaceuticals’ Thin-Film Freezing technology to manufacture dry powder formulations of these specific mAbs for inhalation delivery directly to the lungs of patients. The Agreement also includes the development of formulations suitable for parenteral administration, where the Thin Film Freezing dry powder formulations can be reconstituted, potentially mitigating the impacts of cold-chain storage and handling. TFF Pharmaceuticals will also have the option to develop two additional Augmenta mAbs for indications other than COVID-19.

Augmenta Bioworks and TFF Pharmaceuticals will allocate patent license rights to their respective technologies to allow each company to jointly commercialize the products developed under the Joint Development Project. The companies have agreed to a 50-50 split of all costs and expenses to further the Joint Development Project and both companies have agreed to the same 50-50 split of all revenues, cash payments and/or future cash payments related to the sale and/or license of the products resulting from the Joint Development Project to a third party.

“This important agreement represents the culmination of many months of work by our scientific team, as we work towards the development of a never-before-achieved formulation of monoclonal antibodies into a dry powder therapeutic,” said Glenn Mattes, CEO, of TFF Pharmaceuticals, Inc. “It is a testament to the remarkable flexibility and capability of our Thin Film Freezing platform and we are eager to develop these potentially breakthrough mAb therapies internally, along with our other programs in Invasive Pulmonary Aspergillosis, solid organ transplant anti-rejection, and botanicals.”

“Confirmed discovery of novel anti-SARS-Cov-2 antibodies in 8 days was an achievement made possible by years of technology development, and a clear indication of the power and potential of our platform,” said Christopher Emig, Ph.D., CEO and Co-Founder of Augmenta Bioworks, Inc. “We are excited to enter this partnership to bring our COVID-19 treatment into clinical development, and are looking forward to the world’s first effective, affordable and scalable antibody therapeutic to mitigate the devastating effects of this disease.”

“We believe the interest in monoclonal-antibody therapeutics for the treatment of COVID-19 is extremely high, with the promise that they will harness the immune system’s natural response to viral invaders,” said Robert O. Williams III, Ph.D., Division Head of the University of Texas at Austin’s Division of Molecular Pharmaceutics and Drug Delivery and inventor of TFF Pharmaceuticals’ Thin Film Freezing technology.

“The challenge

Read more

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

MELBOURNE, Australia, Oct. 25, 2020 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Cogstate, Ltd. (Headquarters: Melbourne, Australia and New Haven, USA, CEO: Brad O’Connor, “Cogstate”) announced today that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the “Cogstate Brief BatteryTM” (CBB) for use in healthcare and other markets. This global licensing deal is an expansion of an existing partnership executed in August 2019 whereby Eisai secured exclusive development and commercialization rights in Japan for all cognitive function tests developed by Cogstate, including the CBB. Both companies plan to proceed with development globally of CBB as a tool for individuals to self-assess brain performance to support healthy lifestyle choices and preventative measures in daily life, as well as a medical device to aid healthcare professionals in clinical diagnosis decisions.    

Logo
Logo

Developed by Cogstate, the CBB is a scientifically validated digital tool that enables cognitive function self-checks and consists of four tests evaluating psychomotor function, attention, learning and memory, and working memory. In the United States, Europe, Australia, New Zealand and Canada, the CBB has been adapted as a medical device named “CognigramTM” that has achieved marketing authorization by regulators in these jurisdictions and provides informative results for healthcare professionals to support clinical examination to aid in the diagnosis of MCI and dementia.

In its medium-term business plan, EWAY2025, Eisai is aiming to become a “Medico Societal Innovator” (a company that changes society through creating medicines and providing solutions). Eisai is creating next-generation medical remedies focused on the neurology and oncology areas as well as building disease ecosystem platforms, in order to provide environments and solutions including digital solutions for early diagnosis and early treatment.

Cogstate aims to make assessment of brain health as simple, common and informative as assessment of blood pressure. Cogstate’s technology, which is easy to use and available in over 70 languages, is supported by extensive scientific validation, including more than 600 peer reviewed publications. Cogstate technology has been used extensively in clinical trials, including trials conducted by Eisai.

The global agreement between Eisai and Cogstate will allow the two companies to replicate many of the advancements that have already been launched in Japan, where Eisai has developed and launched a new digital tool using the CBB, named “NouKNOWTM” (pronounced “NOH-NOH”), a non-medical device for self-assessment of brain performance (brain health). Eisai is currently investigating the possibility of developing a medical device using the CBB in Japan.

In recent years, various research has demonstrated the possibility that decline in brain performance may be mitigated through major readjustments to lifestyle, such as regular exercise and sleep, a well-balanced diet, and social interaction. However, according to a survey by Eisai, the number of people taking correct preventive actions or habitually performing self-checks of cognitive function

Read more

VoxNeuro and The Canadian Football League Alumni Association Sign Collaboration Agreement

CFLAA Will Offer VoxNeuro’s Cognitive Health Assessments™ to Its Members

VoxNeuro and the Canadian Football League Alumni Association (CFLAA) are joining forces to offer objective cognitive assessment to CFLAA members, including Canadian football players, former CFL players, and other communities of interest. Through the partnership, these groups will also raise awareness of long term impacts of head trauma, like concussion. For ageing Canadians who have experienced head-trauma throughout their lives, a growing concern is understanding its relationship with cognitive decline.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005188/en/

Legends Luncheon with Canadian Football League Alumni Association members. Courtesy of the CFLAA.

Under the terms of the agreement, VoxNeuro and the CFLAA will collaborate to share the message that long-term effects of head-trauma, from concussion and sub-concussive blows, are prevalent, and not exclusive to athletes who have dedicated their lives to playing impact or high-risk sports. Brain injuries can happen to anyone and each injury is unique – meaning they need to be assessed and treated accordingly.

“We are excited about our collaboration with VoxNeuro. The CFLAA is committed to provide health and wellness support to our members and to the community we serve. We can only do that by aligning with like minded partners. VoxNeuro and its team are such a partner.” – Leo Ezerins, Executive Director and Founder of CFLAA

The CFLAA and VoxNeuro will introduce a significant new neurotechnology to support the health of the CFLAA’s members. The neurotechnology, which assesses cognitive function in an easily accessible clinical setting, will give guidance to providing a solution to any cognitive deficiencies the CFLAA members are experiencing.

This partnership and neurotechnology have a historical tie – VoxNeuro was founded following a breakthrough study of ex-CFL players that used the neurotechnology VoxNeuro has since advanced and made clinically available, called Cognitive Health Assessments™.

VoxNeuro’s Cognitive Health Assessments™ combine imaging and functional tests, drawing on strengths from the most trusted brain assessments used clinically today. The data provided in a patient report differentiates between true cognitive decline and perceived decline due to symptoms caused by situational factors, such as stress, general fatigue or mood.

The ability to make these differentiations is massively impactful for this patient population who are uncertain about the health of their brain, and long-term impacts they may be experiencing from historical injuries. Regardless of the time post injury, the reports help healthcare professionals create targeted plans specific to a patient’s needs and track their performance over time.

VoxNeuro’s technology is the only cognitive assessment in the world today that uses objective, quantifiable neurophysiological data to inform healthcare providers & patients with the specifics of various cognitive brain functions, such as:

  • Executive Function

  • Memory

  • Information Processing

  • Concentration

  • Attention

  • Language Comprehension

The awareness campaign will involve various speaking engagements, events and collaborations with other not-for-profit organizations focused on brain health that both groups actively collaborate with, following the mission to improve brain health across Canada.

“Many CFLAA members have experienced numerous concussive and sub-concussive blows

Read more